Literature DB >> 16275868

Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy.

Ferhaan Ahmad1, Michael Arad, Nicolas Musi, Huamei He, Cordula Wolf, Dorothy Branco, Antonio R Perez-Atayde, David Stapleton, Deeksha Bali, Yanqiu Xing, Rong Tian, Laurie J Goodyear, Charles I Berul, Joanne S Ingwall, Christine E Seidman, J G Seidman.   

Abstract

BACKGROUND: AMP-activated protein kinase (AMPK) regulatory gamma2 subunit (PRKAG2) mutations cause a human cardiomyopathy with cardiac hypertrophy, preexcitation, and glycogen deposition. PRKAG2 cardiomyopathy is recapitulated in transgenic mice overexpressing mutant PRKAG2 N488I in the heart (TGgamma2N488I). AMPK is a heterotrimeric kinase consisting of 1 catalytic (alpha) and 2 regulatory (beta and gamma) subunits. Two alpha-subunit isoforms, alpha1 and alpha2, are expressed in the heart; however, the contribution of AMPK utilization of these subunits to PRKAG2 cardiomyopathy is unknown. Mice overexpressing a dominant-negative alpha2 subunit of AMPK (TGalpha2DN) provide a tool for selectively inhibiting alpha2, but not alpha1, subunit-associated AMPK activity. METHODS AND
RESULTS: In compound-heterozygous TGgamma2N488I/TGalpha2DN mice, AMPK activity associated with alpha2 but not alpha1 was decreased compared with TGgamma2N488I. The TGalpha2DN transgene reduced the disease phenotype of TGgamma2N488I, partially or completely normalizing the ECG, cardiac function, cardiac morphology, and exercise capacity in compound-heterozygous mice. TGgamma2N488I hearts had normal resting levels of high-energy phosphates and could improve cardiac performance during exercise. Cardiac glycogen content decreased in TGgamma2N488I mice after exercise stress, indicating availability of the stored glycogen for metabolic utilization. No differences in glycogen-metabolizing enzymes were observed.
CONCLUSIONS: The PRKAG2 N488I mutation causes inappropriate AMPK activation, which leads to glycogen accumulation and conduction system disease. The accumulated glycogen can serve as an energy source, and the animals have contractile reserve during exercise. Because the dominant-negative alpha2 subunit attenuates the mutant PRKAG2 phenotype, AMPK complexes containing the alpha2 rather than the alpha1 subunit are the primary mediators of the effects of PRKAG2 mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275868     DOI: 10.1161/CIRCULATIONAHA.105.550806

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

Review 1.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies.

Authors:  Hossein Ardehali; Hani N Sabbah; Michael A Burke; Satyam Sarma; Peter P Liu; John G F Cleland; Aldo Maggioni; Gregg C Fonarow; E Dale Abel; Umberto Campia; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2012-02       Impact factor: 15.534

Review 2.  Clinical Spectrum of PRKAG2 Syndrome.

Authors:  Andrea Giuseppe Porto; Francesca Brun; Giovanni Maria Severini; Pasquale Losurdo; Enrico Fabris; Matthew R G Taylor; Luisa Mestroni; Gianfranco Sinagra
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-01

3.  Electrocardiographic Characterization of Cardiac Hypertrophy in Mice that Overexpress the ErbB2 Receptor Tyrosine Kinase.

Authors:  Polina Sysa-Shah; Lars L Sørensen; M Roselle Abraham; Kathleen L Gabrielson
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

Review 4.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

5.  Cardiomyocyte-specific deletion of Sirt1 gene sensitizes myocardium to ischaemia and reperfusion injury.

Authors:  Lin Wang; Nanhu Quan; Wanqing Sun; Xu Chen; Courtney Cates; Thomas Rousselle; Xinchun Zhou; Xuezhong Zhao; Ji Li
Journal:  Cardiovasc Res       Date:  2018-05-01       Impact factor: 10.787

Review 6.  Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Authors:  Tian Li; Shuai Jiang; Zhi Yang; Zhiqiang Ma; Wei Yi; Dongjin Wang; Yang Yang
Journal:  Cell Mol Life Sci       Date:  2016-11-04       Impact factor: 9.261

Review 7.  AMP-activated protein kinase regulation and biological actions in the heart.

Authors:  Vlad G Zaha; Lawrence H Young
Journal:  Circ Res       Date:  2012-08-31       Impact factor: 17.367

Review 8.  Guidelines for animal exercise and training protocols for cardiovascular studies.

Authors:  David C Poole; Steven W Copp; Trenton D Colburn; Jesse C Craig; David L Allen; Michael Sturek; Donal S O'Leary; Irving H Zucker; Timothy I Musch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-20       Impact factor: 4.733

9.  Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.

Authors:  Chang Xie; Ya-Ping Zhang; Lu Song; Jie Luo; Wei Qi; Jialu Hu; Danbo Lu; Zhen Yang; Jian Zhang; Jian Xiao; Bin Zhou; Jiu-Lin Du; Naihe Jing; Yong Liu; Yan Wang; Bo-Liang Li; Bao-Liang Song; Yan Yan
Journal:  Cell Res       Date:  2016-08-30       Impact factor: 25.617

10.  Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.

Authors:  Cordula M Wolf; Michael Arad; Ferhaan Ahmad; Atsushi Sanbe; Scott A Bernstein; Okan Toka; Tetsuo Konno; Gregory Morley; Jeffrey Robbins; J G Seidman; Christine E Seidman; Charles I Berul
Journal:  Circulation       Date:  2007-12-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.